Cross-reactivity with cortisone was ,4% between 3 nmol/L and 20 nmol/L. No carry-over was observed in the SCC assay after assaying salivary samples for cortisol (,0.005% after a saliva sample with an SCC concentration of 1800 mg/L).
Incorrect use of ratios in commercial assay kit instructions
Many tests in clinical laboratories use fully automated 'closed systems' but others use manual techniques or generic 'open systems' such as enzyme immunoassay (EIA) plate processors. These latter techniques rely on accurate manufacturers' instruction sheets. Errors in these have implications on patients and unambiguous instructions are important.
Kit instructions often use the terms 1:x and 1/x interchangeably in describing dilution steps despite these having distinct meanings. Instruction to dilute a sample 1:10 indicates addition of one part of sample to 10 parts of diluent, whereas 1/10 indicates addition of one part to nine parts of diluent. Discussion with a small number of scientists in our laboratory demonstrated that some considered the terms interchangeable.
Current kit inserts from tests within our immunology department were reviewed to determine the extent of this problem in an area that uses many manual assays. Selected commercial kits that required a manual dilution step or set-up on an 'open system' EIA processor were examined. The instruction and intended meaning were determined by careful reading of all parts of the kit insert.
Seventeen kits from seven manufacturers were examined: The Binding Site, Birmingham, UK (anti-gliadin EIA); Technochrome, Vienna, Austria (functional C1 inhibitor kinetic assay); Euroimmun, Lü beck, Germany (anti-intrinsic factor EIA, MPO-ANCA EIA, PR3-ANCA EIA, anti-liver antibody line immunoblot, anti-extractable nuclear antigen [ENA] line immunoblot); SeraQuest, Miami, FL, USA (ENA Plus screen EIA); Aesku Diagnostics, Wendelsheim, Germany (IgA anti-tissue transglutaminase [tTG] EIA). Eight assays from two fully automated systems that provided instructions for off-line dilution of reagents or samples with high results were included: Architect, Abbott Diagnostics, Maidenhead, UK (total prostate-specific antigen, folate, prolactin, vitamin B 12 , total b-human chorionic gonadotropin [hCG]); DELFIA Xpress, Perkin-Elmer, Turku, Finland (alpha-fetoprotein, unconjugated estriol, free-b-hCG).
Of the kits examined only two used the ratio term correctly (The Binding Site anti-gliadin and SeraQuest anti-ENA screen). The other 15 used the ratio as though it was a fraction to describe the dilution of samples or reagents. In all cases the correct meaning could be discerned by careful reading of the kit insert, e.g. Aesku anti-tTG instructs 'Dilute the concentrated sample buffer 1:5 with distilled water (e.g. 20 mL plus 80 mL)'. The clear intention here is a 1/5 dilution, not a 1:5 (1/6). All errors were of this nature, i.e. use of a ratio as equivalent to the fraction. The nature of the error often implied that this was a clear misunderstanding and not an oversight by the manufacturer, e.g. describing a 10 mL plus 1000 mL dilution as 1:101 when it should be 1:100.
When standards, controls and samples are treated identically, even a 1:10 compared with a 1/10 dilution is unlikely to have a significant effect on the results. However, some kits provide prediluted standards and controls but samples require dilution.
It may seem pedantic to insist upon the correct use of these mathematical terms, especially as in the examples seen a careful reading of the kit insert prevented an error. However, the potential for error exists and use of fractions and ratios as equivalent fosters misunderstanding about standard mathematical nomenclature that should be unambiguous and may have consequences elsewhere when correct use of these terms may be critical. Two cases of antiruthenium antibody interference in Modular free thyroxine assay Laboratory tests are important for the diagnosis of both hypothyroidism and hyperthyroidism because of the lack of specificity of the typical clinical manifestations of these disorders. Thyroid function is usually monitored by measuring thyroid-stimulating hormone (TSH) in combination with free thyroxine (fT4) and sometimes free triiodothyronine (fT3). In our hospital, these hormones are measured with immunoassays from Roche Diagnostics (Mannheim, Germany) using monoclonal antibodies with a ruthenium complex. Two female patients are described here, who had results that were difficult to explain. The first patient was taking levothyroxine because of hypothyroidism. We measured a very high fT4 concentration of 85 pmol/L. Her general practitioner doubted the validity of this result given that the patient did not appear thyrotoxic. He therefore referred her to another laboratory for thyroid hormone measurement using a different method (Architect, Abbott, IL, USA). A fT4 concentration of 24 pmol/L was reported (Table 1) . After deliberation, the second sample was also measured with our Roche immunoassay, and again a very high fT4 concentration of 75 pmol/L was observed. The second patient was referred within our hospital to the endocrinologist with elevated thyroid hormone concentrations and a normal TSH: thyroid function tests had been measured because of hair loss. This raised the possibility of two rare disorders, i.e. thyroid hormone resistance and a TSH-secreting pituitary adenoma. However, analysis of that sample with another immunoassay system (Autodelfia, Perkin-Elmer, MA, USA) demonstrated a completely normal TSH, fT4 and fT3 (Table 1) .
There are many causes of interference in immunoassays 1 -3 including heterophilic antibodies, antithyroid hormone antibodies, rheumatoid factor (RF) and interfering drugs. 4 As far as possible these were excluded in these two samples using a heterophilic blocking tube, measuring RF, and screening for drug use. The difference between our findings and the immunoassays in other laboratories led to the conclusion that the results were due to another interfering factor. Because the fT3 assay is known to be sensitive to antiruthenium antibodies, 5,6 the samples of these two women were analysed in Roche Diagnostics Laboratory. In both patients, an interference against ruthenium label was detected, explaining the interference in our fT3 and fT4 assays.
As far as we know, this is the first report that demonstrates interference of antiruthenium antibodies in the Roche fT4 assay. Interference of antiruthenium antibodies in the Roche fT3 assay has been described previously. 5,6 Sapin et al. described that the antiruthenium antibodies in their study did not interfere with the fT4 assay, and in the paper of Ando et al. antiruthenium antibodies seemed to interfere at least partially in the fT4 assay, but could not be confirmed. In our patients, the interference of the antiruthenium antibodies was similar in the fT4 and the fT3 assay. Allthough ruthenium was also present in the TSH assay, we did not observe its interference in that assay. Although our results are in accord with the previous studies, 5,6 we do not have an explanation of why the interference is not seen in the TSH assay.
Antiruthenium antibodies are relatively common ( prevalence of 0.2% 6 ), and may therefore be an important laboratory and clinical problem. In earlier papers 5,6 it was assumed that Roche overcame this problem in the fT3 assay using a new blocking protein in reagents from 2006. However, our samples were measured between April 2007 and August 2008, suggesting that at least not all problems with antiruthenium antibodies had been solved. Roche Female 0.32 (0.3 -4.5) 26 (11 -22) 11.0 (3.5 -6.5) 13 (0.5 -5.0) † 12.8 (10 -23) † 6.3 (4.5 -7.5) † Locally derived reference values appropriate for the assays cited are given in brackets after the results. nd: not determined Ã Determined by Architect † Determined by Autodelfia
